11 May 2020
Adalvo, the new B2B company as part of the Alvogen and Alvotech family, have worked with Lotus pharmaceuticals in Asia to announce 10 new strategic partnership agreements in 2020 with some of the world’s leading pharmaceutical companies. The regions covered by these partnerships include the European Union, Middle East and North Africa (MENA), South Africa, Israel, Canada, Brazil and Columbia.
Lotus will be responsible for the development and manufacturing of the products for its partners that include Lenalidomide, Sunitinib, Enzalutamide.
This is another step forward for the Alvo family, driven by the inception of Adalvo and a continued focus on B2B growth. Along with this announcement, recent partnership agreements have also been made for products still under development coming from Lotus’ leading oncology portfolio.